Sorrento Therapeutics's Total Assets for the quarter that ended in Jun. 2023 was $456.69 Mil.
During the past 12 months, Sorrento Therapeutics's average Total Assets Growth Rate was -24.60% per year.
During the past 3 years, the average Total Assets Growth Rate was -7.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 1.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 50.00% per year.
During the past 13 years, Sorrento Therapeutics's highest 3-Year average Total Assets Growth Rate was 429.60%. The lowest was -7.50%. And the median was 73.50%.
Sorrento Therapeutics Total Assets Historical Data
The historical data trend for Sorrento Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Sorrento Therapeutics's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sorrento Therapeutics (OTCPK:SRNE) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Jun. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Sorrento Therapeutics's Asset Turnover for the quarter that ended in Jun. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Sorrento Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Sorrento Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Sorrento Therapeutics (Sorrento Therapeutics) Business Description
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRNE has been successfully added to your 